Watchlist

Watchlist
Ardelyx, Inc. (ARDX)
Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
FREMONT, Calif. , Dec. 11, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agreement with Shanghai FosunPharmaceutical Industrial Development Company Limited (Fosun Pharma) providing Fosun Pharmawith the exclusive r…
Ardelyx Could Be A Contrarian Opportunity
Ardelyx ( ARDX ) is a $310 million market cap company trading at $6.50 per share focused on developing therapeutics for the treatment of gastrointestinal ((GI)) and cardiorenal diseases. Strong Bio is forming a contrarian investment strategy for ARDX, based upon recent phase 3 results that i…
Your Daily Pharma Scoop: Omeros If And Buts, Egalet's Oxycodone Success, Auris Flunks Study
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Omeros Corp Today we will cover…
Premarket Gainers as of 9:05 am
APEN +35% as FDA clears Apollo's new endoscopic suturing system. More news on: Apollo Endosurgery, Pareteum Corporation, Christopher & Banks Corporation, Stocks on the move, Read more …
Ardelyx and Kyowa Hakko Kirin inks deal for Tenapanor for Cardiorenal diseases in Japan; ARDX up 13% premarket
Ardelyx (NASDAQ: ARDX ) and Kyowa Hakko Kirin ( OTCPK:KYKOF ) announces that they have entered into a license agreement that provides Kyowa Hakko Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal dis…
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
FREMONT, Calif. and TOKYO , Nov. 28, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) and Kyowa Hakko Kirin Co., Ltd. ( Tokyo : 4151, "Kyowa Hakko Kirin"), today announced that they have entered into a license agreement that provides Kyowa Hakko Kirin with exclusive rights to develop a…
Your Daily Pharma Scoop: Teva Valuation, DelMar Lead Candidate, Galapagos Commences Trial
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Teva Today we will discuss an article …
Ardelyx prepares to launch second late-stage study of hyperphosphatemia med tenapanor, development of hyperkalemia candidate RDX7675 terminated; shares up 7% premarket
Ardelyx (NASDAQ: ARDX ) is up 7% premarket on modest volume on the heels of its announcement that enrollment will begin shortly in a second Phase 3 study assessing lead candidate tenapanor for the treatment of hyperphosphatemia (excess phosphate in the blood) in end-stage renal…
Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
FREMONT, Calif. , Nov. 21, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia will begin enrolling shortly, after having rec…
After Hours Gainers / Losers
Top gainers, as of 5.25 p.m.: ASYS +13.3% . PANW +5.9% . CRR +3.8% . ARDX +3.6% . VCO +3.6% . More news on: Amtech Systems, Inc., Palo Alto Networks, CARBO Ceramics Inc., Stocks on the move, Read more …
The Stock Market Cycle And Implications For Medical Stock Investing
Nearly one year ago, I wrote that my target DJIA price for 2017 was 23,000. Furthermore, I stated that this first leg of the bull market would not end until the small and micro cap medical stocks had advanced. Both of these events have occurred. The first leg of this bull market began in 200…
Ardelyx, Inc. (ARDX)